Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).
作者信息
Swan Dawn, Delaney Caoimhe, Natoni Alessandro, O'Dwyer Michael, Krawczyk Janusz
机构信息
University Hospital Galway
National University of Ireland, Galway, Ireland.
出版信息
Haematologica. 2020 Mar;105(3):e141-e143. doi: 10.3324/haematol.2019.228338. Epub 2019 Nov 21.
Abstract
摘要
相似文献
1
Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).
Haematologica. 2020 Mar;105(3):e141-e143. doi: 10.3324/haematol.2019.228338. Epub 2019 Nov 21.
2
Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax.用一例对维奈托克敏感的难治性疾病解释多发性骨髓瘤中t(11;14)的生物学意义
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e556-e559. doi: 10.1016/j.clml.2020.05.028. Epub 2020 Jun 14.
3
Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.卡非佐米、维奈克拉和地塞米松用于复发/难治性多发性骨髓瘤
Br J Haematol. 2020 May;189(3):e73-e76. doi: 10.1111/bjh.16483. Epub 2020 Feb 3.
4
Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).在一名患有非常晚期难治性骨髓瘤且伴有t(11;14)易位的患者中，维奈克拉治疗后出现深度且持续的缓解。
Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5.
5
Venetoclax salvage therapy in relapsed/refractory multiple myeloma.维奈托克挽救疗法用于复发/难治性多发性骨髓瘤
Haematologica. 2024 Mar 1;109(3):979-981. doi: 10.3324/haematol.2023.283472.
6
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.靶向 Venetoclax 治疗 t(11;14)多发性骨髓瘤：来自七个匈牙利中心的真实世界数据。
Pathol Oncol Res. 2022 Feb 28;28:1610276. doi: 10.3389/pore.2022.1610276. eCollection 2022.
7
Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.维奈托克难治性多发性骨髓瘤患者的自然病史：单中心经验。
Am J Hematol. 2021 Mar 1;96(3):E68-E71. doi: 10.1002/ajh.26064. Epub 2020 Dec 28.
8
Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.尽管有负面试验，但 Venetoclax 在 t(11;14)多发性骨髓瘤中的持续成功。
Oncology (Williston Park). 2024 Jun 10;38(6):239-241. doi: 10.46883/2024.25921023.
9
Venetoclax for the treatment of multiple myeloma.维奈托克治疗多发性骨髓瘤。
Expert Rev Hematol. 2018 Dec;11(12):915-920. doi: 10.1080/17474086.2018.1548931. Epub 2018 Dec 6.
10
Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.低剂量维奈托克联合硼替佐米、达雷妥尤单抗和地塞米松治疗复发/难治性多发性骨髓瘤患者的单中心回顾性研究。
Ann Hematol. 2021 Aug;100(8):2061-2070. doi: 10.1007/s00277-021-04555-3. Epub 2021 May 14.
引用本文的文献
1
Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14).伴有 t(6;14)易位的复发/难治性多发性骨髓瘤患者中有效的维奈托克治疗。
Pathol Oncol Res. 2023 Nov 10;29:1611375. doi: 10.3389/pore.2023.1611375. eCollection 2023.
2
Administration of combined venetoclax and azacitidine in a patient with acute myeloid leukemia and multiple comorbidities undergoing dialysis: A case report.在一名接受透析的急性髓系白血病合并多种合并症患者中联合使用维奈托克和阿扎胞苷：病例报告
EJHaem. 2023 Jun 6;4(3):841-843. doi: 10.1002/jha2.732. eCollection 2023 Aug.
3
Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease.维奈托克成功治疗一名患有严重慢性肾病的复发性慢性淋巴细胞白血病患者。
Clin Case Rep. 2022 Apr 14;10(4):e05735. doi: 10.1002/ccr3.5735. eCollection 2022 Apr.
4
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.靶向 Venetoclax 治疗 t(11;14)多发性骨髓瘤：来自七个匈牙利中心的真实世界数据。
Pathol Oncol Res. 2022 Feb 28;28:1610276. doi: 10.3389/pore.2022.1610276. eCollection 2022.
5
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor.多发性骨髓瘤治疗中免疫治疗之外的新型方法：美法仑氟芬、维奈克拉和塞利尼索的案例
Front Oncol. 2021 Sep 30;11:716751. doi: 10.3389/fonc.2021.716751. eCollection 2021.
本文引用的文献
1
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.CyBorD-DARA 是治疗 MM 的有效初始诱导方案，并增强 ADCP：16-BCNI-001/CTRIAL-IE 16-02 研究的初步结果。
Blood Adv. 2019 Jun 25;3(12):1815-1825. doi: 10.1182/bloodadvances.2019000010.
2
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Venetoclax 作为靶向治疗复发/难治性 t(11;14)多发性骨髓瘤的疗效。
Blood. 2017 Nov 30;130(22):2401-2409. doi: 10.1182/blood-2017-06-788786. Epub 2017 Oct 10.
3
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.硼替佐米和地塞米松联合维奈托克治疗复发/难治性多发性骨髓瘤显示出良好的疗效和可接受的安全性。
Blood. 2017 Nov 30;130(22):2392-2400. doi: 10.1182/blood-2017-06-788323. Epub 2017 Aug 28.
4
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.泊马度胺、硼替佐米和地塞米松用于复发的来那度胺难治性多发性骨髓瘤患者。
Blood. 2017 Sep 7;130(10):1198-1204. doi: 10.1182/blood-2017-05-782961. Epub 2017 Jul 6.
5
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.多发性骨髓瘤：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv52-iv61. doi: 10.1093/annonc/mdx096.
6
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.新型BCL-2抑制剂维奈托克在复发或难治性慢性淋巴细胞白血病或非霍奇金淋巴瘤患者中的药代动力学
J Clin Pharmacol. 2017 Apr;57(4):484-492. doi: 10.1002/jcph.821. Epub 2016 Nov 15.
7
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.BCL-2、BCL-XL和MCL-1的表达谱预测多发性骨髓瘤模型对BCL-2选择性拮抗剂维奈托克的药理反应。
Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.
8
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.细胞遗传学分类对多发性骨髓瘤早期大剂量治疗后结局的影响。
Leukemia. 2016 Mar;30(3):633-9. doi: 10.1038/leu.2015.287. Epub 2015 Oct 21.
9
Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System.基于基因表达和国际分期系统预测高危和低危多发性骨髓瘤。
Blood. 2015 Oct 22;126(17):1996-2004. doi: 10.1182/blood-2015-05-644039. Epub 2015 Sep 1.
10
Reprogramming cell death: BCL2 family inhibition in hematological malignancies.重编程细胞死亡：血液系统恶性肿瘤中 BCL2 家族抑制。
Immunol Lett. 2013 Sep-Oct;155(1-2):36-9. doi: 10.1016/j.imlet.2013.09.015. Epub 2013 Oct 1.
Zotero 插件